ValiRx and StingRay Bio collaborate on preclinical cancer therapeutics research

ValiRx Plc (AIM: VAL), a pioneering life science company, has entered into a strategic agreement with StingRay Bio Limited to evaluate a series of drug candidates for cancer therapy. The collaboration focuses on an innovative series of molecules developed by StingRay, designed to target kinases linked to cancer.

Innovative Approach in Oncology Drug Development

Under the terms of the agreement, ValiRx will conduct a series of preclinical tests over the next twelve months. These tests are aimed at validating StingRay’s technology and determining the commercial viability of the drug candidates. The preclinical evaluation will span various cancer types, leveraging research conducted at Inaphaea BioLabs and other collaborative partners.

ValiRx’s Commitment to Advancing Cancer Therapeutics

The research will involve lead optimization and assessment of the molecules’ activity and safety profiles, using patient-derived cells from ValiRx’s recently acquired Imagen biobank. Dr. Suzy Dilly, CEO of ValiRx, expressed enthusiasm for the project, citing the high caliber of medicinal chemistry involved.

Collaborative Efforts in Cancer Drug Optimization

Jeff Roix, CEO of StingRay Bio, looks forward to the collaboration’s progress, emphasizing ValiRx’s innovative capabilities with its Inaphaea team and novel Imagen assets. The agreement, capped at £100,000 for the twelve-month period, offers ValiRx an option to license the technology upon completion.

About ValiRx and StingRay Bio Limited:

ValiRx, specializing in early-stage cancer therapeutics and women’s health, collaborates with StingRay Bio Limited in a groundbreaking venture to develop and commercialize cancer treatment solutions.